Fig. 1.
Plasma ceramides and monohexosylceramides among individuals with autopsy-confirmed Lewy body pathology or AD pathology. Standardized methods for sampling and neuropathologic examination were performed according to the third report of the DLB consortium (CDLB) and the Consortium to Establish a Registry for Alzheimer's Disease guidelines. CN, Cognitively normal, normal aging pathology; DLB, Dementia with Lewy Bodies (high or intermediate likelihood); AD, Dementia with Alzheimer's disease pathology. *P < .05 versus NC; **P < .01 versus NC; †P < .05 versus intermediate-likelihood DLB; ‡P < .001 vs. intermediate-likelihood DLB.